Top

Supportive Care in Cancer

Published in:

01-08-2009 | Short Communication

Depression in lung cancer patients: is the HADS an effective screening tool?

Authors: Lorys Castelli, Luca Binaschi, Paola Caldera, Riccardo Torta

Published in: Supportive Care in Cancer | Issue 8/2009

Abstract

Introduction

The present study aimed at comparing the efficacy in recognizing depression, in 53 patients newly diagnosed with lung cancer, of the Hospital Anxiety and Depression Scale (HADS), a self-report screening questionnaire, and the Montgomery-Asberg Depression Rating Scale (MADRS), a semi-structured clinician-rated interview. Specifically, we aimed at addressing the question of which is the best HADS cutoff for the detection of patients to be further investigated through a clinical semi-structured interview (the MADRS).

Results

The MADRS identified 92% of the patients as depressed; the HADS, 70% and 87%, using a cutoff of 11 and 8, respectively. The results suggest substantial agreement between the HADS and the MADRS when a cutoff of 8 is used (McNemar: p = 0.51; Cohen K = 0.69), while a HADS cutoff of 11 resulted in a significantly lower concordance with the MADRS (McNemar: p = 0.002; Cohen K = 0.49).

Ballenger JC, Davidson JR, Lecrubier Y et al (2001) Consensus statement on depression, anxiety and oncology. J Clin Psychiatry 62:64–67PubMed

Berard RMF, Boermeester F, Viljoen G (1998) Depressive disorders in an out-patient oncology setting: prevalence, assessment, and management. Psychooncology 7:112–120. doi:10.1002/(SICI) 1099-1611(199803/04)7:2<112::AID-PON300>3.0.CO;2-W PubMedCrossRef

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 52:69–77. doi:10.1016/S0022-3999(01)00296-3 PubMedCrossRef

Bulli F, Miccinesi G, Maruelli A, Katz M, Paci E (2008) The measure of psychological distress in cancer patients: the use of Distress Thermometer in the Oncological Rehabilitation Center of Florence. Support Care Cancer. doi:10.1007/s00520-008-0543-9

Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7(3):121–127. doi:10.1007/s005200050241 PubMedCrossRef

Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18(4):893–903PubMed

Johnston M, Pollard B, Hennessey P (2000) Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 48(6):579–584. doi:10.1016/S0022-3999(00)00102-1 PubMedCrossRef

Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP (1982) A comparison of depression rating scales. Br J Psychiatry 141:45–49. doi:10.1192/bjp.141.1.45 PubMedCrossRef

Landis JR, Koch GG (1997) The measurement of observer agreement for categorical data. Biometrics 33:159–174. doi:10.2307/2529310 CrossRef

10.

Lloyd-Williams M, Freidman T, Rudd N (2000) Criterion validation of the Edinburgh postnatal depression scale as a screening tool for depression in patients with advanced metastatic cancer. J Pain Symptom Manage 20:259–265. doi:10.1016/S0885-3924(00)00182-2 PubMedCrossRef

11.

Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71. doi:10.1093/jncimonographs/lgh014 PubMedCrossRef

12.

Massie MJ, Popkin MK (1998) Depressive disorders. In: Holland JC (ed) Psycho-oncology. Oxford University Press, New York, pp 518–540

13.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389. doi:10.1192/bjp.134.4.382 PubMedCrossRef

14.

Muller MJ, Himmerich H, Kienzle B et al (2003) Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 77:255–260. doi:10.1016/S0165-0327(02)00120-9 PubMedCrossRef

15.

Néron S, Correa JA, Dajczman E, Kasymjanova G, Kreisman H, Small D (2007) Screening for depressive symptoms in patients with unresectable lung cancer. Support Care Cancer 15:1207–1212. doi:10.1007/s00520-007-0225-z PubMedCrossRef

16.

Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, Lohr KN (2000) Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136(10):765–776

17.

Reich M (2008) Depression and cancer: recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol 20(4):353–359PubMedCrossRef

18.

Uchitomi Y, Mikami I, Kugaya A, Akizuki N, Nagai K, Nishiwaki Y, Akechi T, Okamura H (2000) Depression after successful treatment for non-small cell lung cancer. Cancer 89:1172–1179. doi:10.1002/1097-0142(20000901)89:5<1172::AID-CNCR27>3.0.CO;2-U PubMedCrossRef

19.

Walker J, Postma K, McHugh GS, Rush R, Coyle B, Strong V, Sharpe M (2007) Performance of the Hospital Anxiety and Depression Scale as a screening tool for major depressive disorder in cancer patients. J Psychosom Res 63(1):83–91. doi:10.1016/j.jpsychores.2007.01.009 PubMedCrossRef

20.

Zimmerman M, Posternak MA, Chelminski I (2004) Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 19(4):215–220. doi:10.1097/01.yic.0000130232.57629.46 PubMedCrossRef

21.

Zimmerman M, Posternak MA, Chelminski I (2004) Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38(6):577–582. doi:10.1016/j.jpsychires.2004.03.007 PubMedCrossRef

Title: Depression in lung cancer patients: is the HADS an effective screening tool?
Authors: Lorys Castelli
Luca Binaschi
Paola Caldera
Riccardo Torta
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 8/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0604-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Results

Please log in to get access to this content

Other articles of this Issue 8/2009

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

Cancer-associated hypercalcemia: validation of a bedside prognostic score

Randomized clinical trial of an intensive nursing-based pain education program for cancer outpatients suffering from pain

Changes in employment and household income during the 24 months following a cancer diagnosis

Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?

The effect of exercise counselling with feedback from a pedometer on fatigue in adult survivors of childhood cancer: a pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer